Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Lymphoma 40Myelodysplastic Syndromes 30Lymphoma, Non-Hodgkin 29Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Follicular 27Leukemia, Myeloid, Acute 26Leukemia, Myeloid, Chronic-Phase 25Leukemia, Lymphocytic, Chronic, B-Cell 24Burkitt Lymphoma 24Leukemia, Myeloid, Accelerated Phase 23Lymphoma, Large-Cell, Immunoblastic 22Multiple Myeloma 20Hodgkin Disease 20Myeloproliferative Disorders 19Lymphoma, Mantle-Cell 18Lymphoma, B-Cell, Marginal Zone 18Graft vs Host Disease 18Blast Crisis 18Neoplasms, Plasma Cell 17Leukemia, Myelomonocytic, Chronic 16Dendritic Cell Sarcoma, Interdigitating 15Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 14Congenital Abnormalities 14Recurrence 13Anemia, Refractory, with Excess of Blasts 13Primary Myelofibrosis 12Myelodysplastic-Myeloproliferative Diseases 12Lymphoma, T-Cell, Cutaneous 10

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Methylprednisolone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡